| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5268408
Max Phase: Preclinical
Molecular Formula: C12H20N6O7
Molecular Weight: 360.33
Associated Items:
Representations
Canonical SMILES: C[C@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc([C@@H](N)CO)no1)C(=O)O
Standard InChI: InChI=1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-17-9(18-25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4-,5-,6-,8-/m0/s1
Standard InChI Key: HFOBENSCBRZVSP-TYQACLPBSA-N
Associated Targets(Human)
Programmed cell death 1 ligand 1 299 Activities
V-type immunoglobulin domain-containing suppressor of T-cell activation 14 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Splenocyte 1641 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 360.33 | Molecular Weight (Monoisotopic): 360.1393 | AlogP: -2.89 | #Rotatable Bonds: 9 |
| Polar Surface Area: 226.92 | Molecular Species: ACID | HBA: 9 | HBD: 7 |
| #RO5 Violations: 1 | HBA (Lipinski): 13 | HBD (Lipinski): 9 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 3.50 | CX Basic pKa: 6.97 | CX LogP: -5.95 | CX LogD: -6.43 |
| Aromatic Rings: 1 | Heavy Atoms: 25 | QED Weighted: 0.24 | Np Likeness Score: -0.60 |
References
| 1. Wu C, Cao X, Zhang X.. (2021) VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses., 12 (10.0): [PMID:34778768] [10.1039/D1MD00185J] |
Source
Source(1):